India’s Semaglutide Surge: Generic GLP-1s Redefine Access and Competition

India’s long-awaited semaglutide patent expiry on March 20 has triggered a wave of generic GLP-1 (glucagon-like peptide-1) launches, poised to dramatically reshape the landscape of diabetes and weight management treatment in the country and potentially globally. The influx of affordable options is expected to redefine access to these medications, test regulatory capacity, and create a highly competitive pharmaceutical market.

The Launch Wave

Within hours of the patent expiry, Dr. Reddy’s Laboratories launched Obeda, the first DCGI-approved semaglutide injection in India. Priced at Rs 4,200 per month for a once-weekly pen, Dr. Reddy’s claims Obeda demonstrates non-inferior efficacy and a comparable safety profile to Novo Nordisk’s innovator product in a Phase III study.

Glenmark Pharmaceuticals quickly followed with GLIPIQⓇ (semaglutide), offering weekly treatment costs starting as low as Rs 325. GLIPIQ is available in both vial and pre-filled pen formulations, approved by the CDSCO after a Phase III trial.

Sun Pharma entered the market with Noveltreat and Sematrinity, targeting both weight management and Type 2 diabetes. Weekly therapy costs range from Rs 750 to Rs 2,000. Noveltreat features a concealed-needle pen, while Sematrinity offers flexible dosing.

Zydus Lifesciences launched three semaglutide brands – SEMAGLYN™, MASHEMA™, and ALTERME™ – immediately upon patent expiry. Zydus differentiates itself with a reusable, multi-dose pen and cartridge system, bringing the average monthly therapy cost to around Rs 2,200.

Natco Pharma adopted a two-brand strategy – SEMANAT and SEMAFULL – with aggressive pricing. Multi-dose vials are available for as low as Rs 1,290 to Rs 1,750 per month, with pre-filled pens priced around Rs 4,000 to Rs 4,500 to follow in April.

A Shift in Affordability

Prior to the patent expiry, Ozempic cost between ₹8,800 and ₹11,175 per month in India, while Wegovy reached ₹16,400. The introduction of generics has drastically lowered these costs, making GLP-1 therapy accessible to a much wider population.

Expanding Market Reach and Partnerships

Dr. Reddy’s Laboratories is partnering with leading domestic companies to co-market its generic semaglutide, Obeda, in India. The company is also pursuing international partnerships to expand its reach beyond initial markets.

Zydus Lifesciences has formed alliances with Lupin and Torrent to accelerate the distribution of its brands.

Regulatory Scrutiny

The Central Drugs Standard Control Organisation (CDSCO) has issued warnings against surrogate advertising and digital marketing promoting GLP-1 drugs for lifestyle weight loss. The Delhi High Court has also requested explanations from the DCGI regarding potential gaps in the approval process for GLP-1 drugs, including concerns about clinical data and pharmacovigilance.

Future Outlook

India’s semaglutide launch is being closely watched globally. If Indian manufacturers can successfully scale production, the country could turn into a major exporter of affordable GLP-1 medications, impacting obesity care economics worldwide. Analysts anticipate 40 to 50 brands will enter the Indian market in the coming weeks, mirroring the rapid proliferation of sitagliptin generics after its patent expiry in 2022.